Stock listing

Shanghai:688506 Sichuan Biokin Pharmaceutical Co., Ltd. (百利天恒) 股价

Follow Sichuan Biokin Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.

Share price · SSE:688506

¥233.88 CNY +2.71 (+1.2%)

Close on Oct 16, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. logo
Ticker
Shanghai:688506
Asset type
Stock
Exchange
Shanghai
Currency
CNY

What changed lately

Latest news

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Issuance Results of the 1st Tranche of Sci-Tech Innovation Bonds for 2026

Oct 16, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in the Priority Review Program for Treatment of EGFR-TKI-Resistant, EGFR-Mutant Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Oct 13, 2026

Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for Yizekang (Izalontamab Brengitecan, BL-B01D1/iza-bren) in Combination with Radiotherapy for the Treatment of Locally Advanced Unresectable Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Oct 12, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital

Sep 30, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Securities Affairs Representative

Sep 30, 2026

Announcement on Voluntary Disclosure of the Completion of Enrollment of the First Subject in the Phase III Clinical Trial of T-Bren for Injection (HER2 ADC) for the Treatment of HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Sep 30, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of T-Bren (HER2 ADC) in the List of Breakthrough Therapy Designations for Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Have Failed Platinum-based Chemotherapy

Sep 28, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of iza-bren (izalontamab brengitecan, BL-B01D1) in the List of Breakthrough Therapy Designations for Patients with Recurrent or Metastatic Biliary Tract Cancer Who Have Failed Prior Platinum-based Chemotherapy

Sep 28, 2026

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BL-M12D1 for Injection (ADC) for the Treatment of Hematological Malignancies

Sep 28, 2026

Announcement on Voluntary Disclosure of the Inclusion of BL-M05D1 for Injection in the List of Breakthrough Therapy Designations for Patients with CLDN18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Previously Received First-line Standard Treatment

Sep 28, 2026

All Sichuan Biokin Pharmaceutical Co., Ltd. news

Financings

  • 2026 1st tranche sci-tech innovation bonds (medium-term notes, 5+5 years, 1.90%)

    Oct 16, 2026 · US$149.48M

    Closed: CNY 1B raised · 上海浦东发展银行股份有限公司

    Dealers: 上海浦东发展银行股份有限公司 (lead)

    Closed Oct 16, 2026

Read by 6ix AI from the company's releases

Sichuan Biokin Pharmaceutical Co., Ltd. on 6ix

News releases
71 in the last 12 months · 93 in all · newest Oct 16, 2026 · oldest 2025

Log in to ask 6ix AI your own questions about Sichuan Biokin Pharmaceutical Co., Ltd.